Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528827 | Current Opinion in Pharmacology | 2017 | 7 Pages |
Abstract
Splicing mutations can lead to aberrantly spliced transcripts by creating a cryptic splice site or destroying a normal site. Most mutations result in disruption of the open reading frame and activation of NMD. Antisense oligonucleotides are single stranded short synthetic RNA-like molecules chemically modified to improve their stability and ability to recognize their target RNAs and modify the splice site. This review focuses on recent developments in therapies aiming to improve the health of CF patients carrying nonsense or splicing mutations.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Yifat S Oren, Iwona M Pranke, Batsheva Kerem, Isabelle Sermet-Gaudelus,